Trial Profile
A 12-WEEK, MULTICENTER, MULTINATIONAL, RANDOMISED, DOUBLE BLIND, DOUBLE-DUMMY (OPEN LABEL FOR THE SPACER GROUP), 3-ARM PARALLEL GROUP STUDY COMPARING THE EFFICACY AND THE SAFETY OF CHF 1535 HFA pMDI (BDP/FF 100/6 microg per actuation) 2 PUFFS BID VERSUS BDP HFA pMDI (250 microg per actuation) 2 PUFFS BID, IN ADOLESCENT PATIENTS WITH MODERATE TO SEVERE PERSISTENT ASTHMA.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Sep 2017
Price :
$35
*
At a glance
- Drugs Beclometasone/formoterol (Primary) ; Beclometasone
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Chiesi Farmaceutici
- 30 May 2012 Actual initiation date changed from 9 Aug 2007 to 11 Jul 2007 as reported by European Clinical Trials Database record.
- 09 Aug 2011 New trial record